etoposide plus carboplatin
Phase 2Small molecule
etoposide plus carboplatin is one of 7 small molecule programs targeting Pulmonary Large Cell Neuroendocrine Carcinoma. It is currently in Phase 2.
1
Indications
1
Total Trials
0
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
6 competitors in Pulmonary Large Cell Neuroendocrine Carcinoma
#DrugCompanyPhaseTrials
1Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Paraplatin
AAvyxa
Approved
Vepesid
AAvyxa
Approved
Imfinzi
AstraZenecaPhase 2
Tecentriq
RochePhase 2
Paclitaxel and Epirubicin
GSKPhase 2
etoposide plus carboplatin
SShanghai Chest Hospital
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for etoposide plus carboplatin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- SShanghai Chest Hospital